This information is intended for US healthcare professionals For patients

OAB Monograph

An estimated 35 million people in the US are affected by overactive bladder*1,2

Photograph of healthcare team having a meeting

Overview of Overactive Bladder

OAB Description

Epidemiology and Relevant Risk Factors

Overactive bladder (OAB), characterized by frequent urinary urgency and nocturia, with or without urge incontinence, affects approximately 35 million people in the US and significantly impairs activities of daily living (ADL). An internet-based survey study among 20,000 US adults ≥40 years found the overall prevalence of OAB to be 23%, with the prevalence of at least “sometimes” to be 27.2% and 43.1% and “often” to be 15.8% and 32.6%, in men and women respectively. The study found… 

* Estimates are based on 23% prevalence rate from the EpiLUTS study and 2018 US Census Bureau population number projections for 2018.

1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
2. US Census Bureau. Age and Sex Composition: 2018. Available at: Sex&tid=ACSST1Y2018.S0101&hidePreview=false. Accessed November 4, 2020.
3. Puckrein G, Walker D, Xu L, Congdon P, Gooch K. The prevalence and forecast prevalence of overactive bladder in the Medicare population. Clin Med Insights Urol. 2019;12. doi:10.1177/1179561119847464

Tell us what interests you

How interested are you in learning more about the following topics?

The role of β3-adrenoreceptor agonists in treating patients with OAB
Comorbidities among patients with OAB
Reducing the potential risk of drug-drug interactions
Clinical burden of OAB
Economic burden of OAB


We’ve received your completed survey. Thanks for participating.


Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.


Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver